drugset
drugset / Trial / NCT00187122

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

NCT00187122 ↗

Completed 42 enrolled St. Jude Children's Research Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.

Timeline

Start
1993-03
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cytarabine Small molecule 300 mg/m2 Intravenous
Subject Daunorubicin Small molecule 25 mg/m2 Intravenous
Subject Dexamethasone Small molecule 8 mg/m2 Oral
Subject Etoposide Small molecule 300 mg/m2 Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule 75 mg/m2 Oral
Subject Methotrexate Small molecule 40 mg/m2 Intramuscular
Subject Methotrexate Small molecule 200 mg/m2 Intramuscular
Subject Methotrexate Small molecule 800 mg/m2 Intramuscular
Subject Methotrexate Small molecule 2 g Intramuscular
Subject Prednisone Other / unclassified 40 mg/m2 Oral
Subject Vincristine Small molecule 0.05 mg/kg Intravenous
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 10000 unknown Intramuscular

Indications

lymphoblastic lymphoma